financetom
Business
financetom
/
Business
/
Cava Group Insider Sold Shares Worth $3,225,851, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cava Group Insider Sold Shares Worth $3,225,851, According to a Recent SEC Filing
Mar 28, 2024 1:46 PM

04:17 PM EDT, 03/28/2024 (MT Newswires) -- Theodoros Xenohristos, Director, on March 26, 2024, sold 47,239 shares in Cava Group ( CAVA ) for $3,225,851. Following the Form 4 filing with the SEC, Xenohristos has control over a total of 526,521 shares of the company, with 526,521 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1639438/000162828024013608/xslF345X03/wk-form4_1711656057.xml

Price: 70.2, Change: +0.15, Percent Change: +0.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Sep 10, 2025
BOSTON, Sept. 10, 2025 /PRNewswire/ -- Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms. The Prinses Máxima Center is the largest pediatric cancer center in Europe, dedicated to integrating care and research to...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
Sep 10, 2025
(Reuters) -The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar. The report said the near term risk from the push to slash prescription drug prices to match those paid...
Kering delays full Valentino acquisition to 2028 amid debt concerns
Kering delays full Valentino acquisition to 2028 amid debt concerns
Sep 10, 2025
PARIS (Reuters) - Kering said on Wednesday that it will not fully buy Italian fashion brand Valentino until at least 2028, its first major move under new CEO Luca de Meo, pushing back the execution of an expensive deal that has been weighing on the heavily indebted group. The deal - announced just a day after de Meo was charged...
Swedish fintech Klarna shares open 30% above IPO price in NYSE debut
Swedish fintech Klarna shares open 30% above IPO price in NYSE debut
Sep 10, 2025
Sept 10 (Reuters) - Shares of Klarna ( KLAR ) opened 30% above their offer price in their New York Stock Exchange debut on Wednesday, giving the Swedish fintech a valuation of $19.65 billion. (Reporting by Arasu Kannagi Basil and Pritam Biswas in Bengaluru) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved